Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
This article clarifies which crypto transactions trigger wash sale rules in 2026 and how they alter reported gains and tax liability.
25,192 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Greg Abel has stepped into Berkshire Hathaway’s top role with a plan that blends steady operations with a measured ap...
Oil prices surge on supply concerns, pushing the S&P 500 lower as investors rotate into energy names. This stock mark...
A fresh global study of tens of thousands of workers finds anxiety about job security dominates, fueled by AI and aut...
Bank Of America boosts its Affirm Holdings target to $88 after a solid quarter, framing May 12 investor day as a cata...
A prominent investor placed a sizable stake in Nektar Therapeutics, sparking questions about the stock's potential. T...
SpaceX has filed its S-1 to go public, presenting a three-pronged business plan that could fund a city on Mars. Here ...
Credo Technology stock sits near its 52-week peak as AI infrastructure demand remains robust. Investors are debating ...
Anthropic is moving toward a public listing, with Amazon and Google as key backers. If the IPO hits a trillion-dollar...
Tech stocks retreat sparked a broader market pause, but analysts insist the stock market isn’t crashing — it’s a rota...
Investors are buzzing after Simulations Plus announced a cash buyout at $18.50 per share. This deep-dive explains why...
Tech stocks tumble second day as investors require evidence that AI investments will pay off, dragging Nvidia, Alphab...